Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
CDDO to Treat Solid Tumors and Lymphomas
Phase I Study of CDDO in Solid Tumors and Lymphomas
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
CDDO to Treat Solid Tumors and Lymphomas
Phase I Study of CDDO in Solid Tumors and Lymphomas
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study
Status: Enrolling
Updated:  9/26/2015
University of California at San Francisco
mi
from
San Francisco, CA
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study
Status: Enrolling
Updated: 9/26/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study
Status: Enrolling
Updated:  9/26/2015
Harvard School of Public Health
mi
from
Boston, MA
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study
Status: Enrolling
Updated: 9/26/2015
Harvard School of Public Health
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study
Status: Enrolling
Updated:  9/26/2015
University of the West Indies
mi
from
Kingston,
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study
Status: Enrolling
Updated: 9/26/2015
University of the West Indies
mi
from
Kingston,
Click here to add this to my saved trials
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated:  9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated: 9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors
Status: Enrolling
Updated:  9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors
Status: Enrolling
Updated: 9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated:  9/29/2015
Site US2778 John B. Amos Cancer Center
mi
from
Columbus, GA
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated: 9/29/2015
Site US2778 John B. Amos Cancer Center
mi
from
Columbus, GA
Click here to add this to my saved trials
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated:  9/29/2015
Site US55 Loyola University Hospital - Maywood
mi
from
Maywood, IL
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated: 9/29/2015
Site US55 Loyola University Hospital - Maywood
mi
from
Maywood, IL
Click here to add this to my saved trials
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated:  9/29/2015
Site US9 Mount Sinai School of Medicine
mi
from
New York, NY
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated: 9/29/2015
Site US9 Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated:  9/29/2015
Site US2802 Mecklenburg Medical Group
mi
from
Charlotte, NC
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated: 9/29/2015
Site US2802 Mecklenburg Medical Group
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated:  9/29/2015
Site US2149 Gabrail Cancer Center Research
mi
from
Canton, OH
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated: 9/29/2015
Site US2149 Gabrail Cancer Center Research
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated:  9/29/2015
Site US402 University of Texas Health Science Center - San Antonio
mi
from
San Antonio, TX
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated: 9/29/2015
Site US402 University of Texas Health Science Center - San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated:  9/29/2015
Site FR1926 Institut Bergonie
mi
from
Bordeaux-cedex,
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant
Status: Enrolling
Updated: 9/29/2015
Site FR1926 Institut Bergonie
mi
from
Bordeaux-cedex,
Click here to add this to my saved trials
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Treatment of B-Cell NHL Relapsing After Transplant With a Rituxan Vinorelbine Combination
Status: Enrolling
Updated:  9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Treatment of B-Cell NHL Relapsing After Transplant With a Rituxan Vinorelbine Combination
Status: Enrolling
Updated: 9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  9/30/2015
Cancer Center and Beckman Research Institute, City of Hope
mi
from
Duarte, CA
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 9/30/2015
Cancer Center and Beckman Research Institute, City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  9/30/2015
Walter Reed Army Medical Center
mi
from
Washington,
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 9/30/2015
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  9/30/2015
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 9/30/2015
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  9/30/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 9/30/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  9/30/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 9/30/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  9/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 9/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  9/30/2015
Cross Cancer Institute
mi
from
Edmonton,
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Rituximab (Rituxan, Mabthera) in Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 9/30/2015
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated:  9/30/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated: 9/30/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated:  9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
An Open-Label Phase I Dose Escalation Trial To Evaluate The Safety And Pharmacokinetics Of Motexafin Gadolinium And Doxorubicin Chemotherapy In The Treatment Of Advanced Malignancies
Status: Enrolling
Updated: 9/30/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073)
Status: Enrolling
Updated:  10/1/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
Quantification of HIV-1 Reservoirs in HIV-Positive Persons Receiving Response-Adapted Therapy for Stage III-IV Hodgkin Lymphoma: A Companion Protocol to SWOG Protocol S0816 (AMC-073)
Status: Enrolling
Updated: 10/1/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
EBV as Therapeutic Target: A Pilot Study of Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma
Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma
Status: Enrolling
Updated:  10/1/2015
University of Wisconsin
mi
from
Madison, WI
Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma
Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia/Lymphoma
Status: Enrolling
Updated: 10/1/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  10/5/2015
University of Chicago
mi
from
Chicago, IL
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 10/5/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
A Phase 1 Study of CTEP 5-Azacytidine in Combination With Oxaliplatin in Patients With Advanced Cancers Relapsed or Refractory or Refractory to Any Platinum Therapy
Status: Enrolling
Updated:  10/5/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
A Phase 1 Study of CTEP 5-Azacytidine in Combination With Oxaliplatin in Patients With Advanced Cancers Relapsed or Refractory or Refractory to Any Platinum Therapy
Status: Enrolling
Updated: 10/5/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome
Status: Enrolling
Updated:  10/5/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome
Status: Enrolling
Updated: 10/5/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome
Status: Enrolling
Updated:  10/5/2015
Albert Einstein Comprehensive Cancer Center
mi
from
Bronx, NY
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome
Status: Enrolling
Updated: 10/5/2015
Albert Einstein Comprehensive Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome
Status: Enrolling
Updated:  10/5/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
Phase II Evaluation of Gallium Nitrate (NSC 15200) in Non-Hodgkin's Lymphoma in Patients With Acquired Immunodeficiency Syndrome
Status: Enrolling
Updated: 10/5/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: Enrolling
Updated:  10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Brief Physician-Initiated Quit Smoking Strategies for Clinical Oncology Settings
Status: Enrolling
Updated: 10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/6/2015
Brigham and Women's Hosp
mi
from
Boston, MA
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/6/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/6/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/6/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/6/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/6/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/6/2015
New York-Presbyterian Hospital
mi
from
New York, NY
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/6/2015
New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/6/2015
Weill Medical College of Cornell University - New York Presbyterian Hospital
mi
from
New York, NY
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/6/2015
Weill Medical College of Cornell University - New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated:  10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
Status: Enrolling
Updated: 10/6/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated:  10/9/2015
Ironwood Cancer and Research Centers SC
mi
from
Chandler, AZ
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated: 10/9/2015
Ironwood Cancer and Research Centers SC
mi
from
Chandler, AZ
Click here to add this to my saved trials
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated:  10/9/2015
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated: 10/9/2015
Highlands Oncology Group Dept of Highlands Oncology Grp
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated:  10/9/2015
USC/Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisMedicalCenter(4)
mi
from
Los Angeles, CA
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated: 10/9/2015
USC/Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisMedicalCenter(4)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated:  10/9/2015
Rocky Mountain Cancer Centers RMCC
mi
from
Greenwood Village, CO
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated: 10/9/2015
Rocky Mountain Cancer Centers RMCC
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated:  10/9/2015
University Cancer Institute
mi
from
Boyton Beach, FL
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Status: Enrolling
Updated: 10/9/2015
University Cancer Institute
mi
from
Boyton Beach, FL
Click here to add this to my saved trials